<H1>Chapter DOI: 10.1186/s12885-016-2397-8<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>27</td></tr><tr><td>Springer references</td><td>3</td></tr><tr><td>Non Springer references</td><td>24</td></tr><tr><td>BibStructured Count</td><td width="10%">25</td></tr><tr><td>BibUnstructured Count</td><td width="10%">2</td></tr><tr><td>DOI already available in SpringerLink</td><td>22</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibBook</td><td>Swerdlow SH, International Agency for Research on C, World Health O. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Bhagavathi S, Sharathkumar A, Hunter S, Sung L, Kanhere R, Venturina MD, Wilson JD Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas. Clinical neuropathology. 2008;27(1):13&#8211;20.</td><td><a href=http://dx.doi.org/10.5414/NPP27013>10.5414/NPP27013</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(2):266&#8211;72.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.09.139>10.1200/JCO.2003.09.139</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J. Primary non-Hodgkin&#8217;s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. International journal of radiation oncology, biology, physics. 2004;59(2):501&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/j.ijrobp.2003.11.001>10.1016/j.ijrobp.2003.11.001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(36):5711&#8211;5.</td><td><a href=http://dx.doi.org/10.1200/JCO.2006.08.2941>10.1200/JCO.2006.08.2941</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(28):3452&#8211;9.</td><td><a href=http://dx.doi.org/10.1200/JCO.2011.41.0985>10.1200/JCO.2011.41.0985</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021&#8211;31.</td><td><a href=http://dx.doi.org/10.1182/blood-2012-10-460063>10.1182/blood-2012-10-460063</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Brunn A, Nagel I, Montesinos-Rongen M, Klapper W, Vater I, Paulus W, Hans V, Blumcke I, Weis J, Siebert R, et al. Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta neuropathologica. 2013;126(4):603&#8211;5.</td><td><a href=http://dx.doi.org/10.1007/s00401-013-1169-7>10.1007/s00401-013-1169-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Gill KZ, Iwamoto F, Allen A, Hoehn D, Murty VV, Alobeid B, Bhagat G. MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system. PloS one. 2014;9(12):e114398.</td><td><a href=http://dx.doi.org/10.1371/journal.pone.0114398>10.1371/journal.pone.0114398</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Tapia</span> <span style='background:#DDDDDD'>G</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Baptista</span> <span style='background:#DDDDDD'>MJ</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Munoz-Marmol</span> <span style='background:#DDDDDD'>AM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gaafar</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Puente-Pomposo</span> <span style='background:#DDDDDD'>M</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Garcia</span> <span style='background:#DDDDDD'>O</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Garcia</span> <span style='background:#DDDDDD'>O</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Marginet-Flinch</span> <span style='background:#DDDDDD'>R</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Sanz</span> <span style='background:#DDDDDD'>C</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Navarro</span> <span style='background:#DDDDDD'>JT</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Sancho</span> <span style='background:#DDDDDD'>JM</span></span>, et al.</aug> MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. <span style='background:#66FF66'>2015</span>;<span style='background:#FFCC66'>123</span>(<span style='background:#C8BE84'>7</span>):<span style='background:#D279FF'>596&#8211;603</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275&#8211;82.</td><td><a href=http://dx.doi.org/10.1182/blood-2003-05-1545>10.1182/blood-2003-05-1545</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Paik JH, Nam SJ, Kim TM, Heo DS, Kim CW, Jeon YK. Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas. BMC cancer. 2014;14:911.</td><td><a href=http://dx.doi.org/10.1186/1471-2407-14-911>10.1186/1471-2407-14-911</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Mahmoud AZ, George TI, Czuchlewski DR, Zhang QY, Wilson CS, Sever CE, Bakhirev AG, Zhang D, Steidler NL, Reichard KK, et al. Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015;28(4):545&#8211;51.</td><td><a href=http://dx.doi.org/10.1038/modpathol.2014.140>10.1038/modpathol.2014.140</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Yoon SO, Jeon YK, Paik JH, Kim WY, Kim YA, Kim JE, Kim CW. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205&#8211;17.</td><td><a href=http://dx.doi.org/10.1111/j.1365-2559.2008.03076.x>10.1111/j.1365-2559.2008.03076.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(28):3460&#8211;7.</td><td><a href=http://dx.doi.org/10.1200/JCO.2011.41.4342>10.1200/JCO.2011.41.4342</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer. 2008;112(1):151&#8211;6.</td><td><a href=http://dx.doi.org/10.1002/cncr.23149>10.1002/cncr.23149</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Tapia G, Baptista MJ, Munoz-Marmol AM, Gaafar A, Puente-Pomposo M, Garcia O, Marginet-Flinch R, Sanz C, Navarro JT, Sancho JM, et al. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. Apmis. 2015;123(7):596&#8211;603.</td><td><a href=http://dx.doi.org/10.1111/apm.12390>10.1111/apm.12390</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Lin CH, Kuo KT, Chuang SS, Kuo SH, Chang JH, Chang KC, Hsu HC, Tien HF, Cheng AL. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(4):1152&#8211;6.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-1699>10.1158/1078-0432.CCR-05-1699</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M, Iraqi W, Sautes-Fridman C, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190&#8211;6.</td><td><a href=http://dx.doi.org/10.1182/blood-2005-03-1024>10.1182/blood-2005-03-1024</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Lossos C, Bayraktar S, Weinzierl E, Younes SF, Hosein PJ, Tibshirani RJ, Sutton Posthumus J, DeAngelis LM, Raizer J, Schiff D, et al. LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. British journal of haematology. 2014;165(5):640&#8211;8.</td><td><a href=http://dx.doi.org/10.1111/bjh.12801>10.1111/bjh.12801</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, Harris NL, Batchelor TT. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003;9(3):1063&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Kreher S, Johrens K, Strehlow F, Martus P, Borowiec K, Radke J, Heppner F, Roth P, Thiel E, Pietsch T, et al. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. Neuro-oncology. 2015;17(7):1016&#8211;21.</td><td><a href=http://dx.doi.org/10.1093/neuonc/nov046>10.1093/neuonc/nov046</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(25):3061&#8211;8.</td><td><a href=http://dx.doi.org/10.1200/JCO.2012.46.9957>10.1200/JCO.2012.46.9957</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Momota H, Narita Y, Maeshima AM, Miyakita Y, Shinomiya A, Maruyama T, Muragaki Y, Shibui S. Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma. Journal of neuro-oncology. 2010;98(3):341&#8211;8.</td><td><a href=http://dx.doi.org/10.1007/s11060-009-0078-z>10.1007/s11060-009-0078-z</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Chang CC, Kampalath B, Schultz C, Bunyi-Teopengco E, Logan B, Eshoa C, Dincer AP, Perkins SL. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Archives of pathology &amp; laboratory medicine. 2003;127(2):208&#8211;12.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Raoux</span> <span style='background:#DDDDDD'>D</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Duband</span> <span style='background:#DDDDDD'>S</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Forest</span> <span style='background:#DDDDDD'>F</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Trombert</span> <span style='background:#DDDDDD'>B</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Chambonniere</span> <span style='background:#DDDDDD'>ML</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Dumollard</span> <span style='background:#DDDDDD'>JM</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Khaddage</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gentil-Perret</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Peoc'h</span> <span style='background:#DDDDDD'>M.</span></span></aug> <span style='background:#CCCCFF'>Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance. Neuropathology : official journal of the Japanese Society of</span> <span style='background:#CCFF99'>Neuropathology</span>. <span style='background:#66FF66'>2010</span>;<span style='background:#FFCC66'>30</span>(<span style='background:#C8BE84'>3</span>):<span style='background:#D279FF'>232&#8211;40</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Hattab EM, Martin SE, Al-Khatib SM, Kupsky WJ, Vance GH, Stohler RA, Czader M, Al-Abbadi MA. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2010;23(2):235&#8211;43.</td><td><a href=http://dx.doi.org/10.1038/modpathol.2009.164>10.1038/modpathol.2009.164</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>